Information  X 
Enter a valid email address

Company Name matching 'F. Hoffmann-La Roche Ltd'

Date
Time Source
Company
Announcement
20 Sep 2021 2:05 pm GNW   F. Hoffmann-La Roche Ltd New Phase III data support the benefit of Roche’s Tecentriq in early-stage lung cancer
17 Sep 2021 12:10 pm GNW   F. Hoffmann-La Roche Ltd Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer
15 Sep 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd Roche opens access to pathology imaging tools to improve patient care
09 Sep 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd Roche signs definitive share purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases
07 Sep 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd Roche to present data from industry leading portfolio at ESMO 2021 showing significant progress in early stage and uncommon cancers
27 Aug 2021 4:45 pm GNW   F. Hoffmann-La Roche Ltd Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer
18 Aug 2021 4:35 pm GNW   F. Hoffmann-La Roche Ltd Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy
09 Aug 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd [Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care
03 Aug 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd US FDA grants Priority Review to Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
29 Jul 2021 6:03 am GNW   F. Hoffmann-La Roche Ltd FDA accepts application for Roche’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
  6:00 am GNW   F. Hoffmann-La Roche Ltd Data for Roche’s Evrysdi® (risdiplam) published in New England Journal of Medicine shows significant improvement in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)
22 Jul 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good half-year results
21 Jul 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes
20 Jul 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19
19 Jul 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd New data for Roche’s Hemlibra reinforce safety profile in people with haemophilia A
09 Jul 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd WHO guidelines now include Roche’s diagnostic tests in expanded effort to eliminate tuberculosis by providing patients greater access to timely diagnosis
02 Jul 2021 2:00 pm GNW   F. Hoffmann-La Roche Ltd Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care
28 Jun 2021 7:00 am GNW   F. Hoffmann-La Roche Ltd Roche’s ENSPRYNG approved by European Commission as first and only at-home subcutaneous treatment for neuromyelitis optica spectrum disorder (NMOSD)
25 Jun 2021 7:00 am GNW   F. Hoffmann-La Roche Ltd Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children
24 Jun 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD)
15 Jun 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd Roche data at EAN 2021 showcase significant impact of therapies across diverse neuroscience portfolio
11 Jun 2021 6:03 am GNW   F. Hoffmann-La Roche Ltd Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia
  6:00 am GNW   F. Hoffmann-La Roche Ltd New Roche data for Evrysdi show improved motor function in pre-symptomatic babies after one year and confirm safety profile in previously treated people with spinal muscular atrophy (SMA)
08 Jun 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd Roche obtains CE mark for the SARS-CoV-2 Antigen Self Test Nasal allowing for rapid self testing of COVID-19 at home
04 Jun 2021 1:00 pm GNW   F. Hoffmann-La Roche Ltd Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma
25 May 2021 1:00 pm GNW   F. Hoffmann-La Roche Ltd European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy
20 May 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd Pivotal Phase III data at ASCO show Roche’s Tecentriq helps certain people with early lung cancer live significantly longer without their disease returning
11 May 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer
05 May 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd Roche’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
28 Apr 2021 9:00 pm GNW   F. Hoffmann-La Roche Ltd US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for previously untreated metastatic bladder cancer
  6:00 am GNW   F. Hoffmann-La Roche Ltd Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people
27 Apr 2021 11:25 pm GNW   F. Hoffmann-La Roche Ltd US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
23 Apr 2021 12:00 pm GNW   F. Hoffmann-La Roche Ltd CHMP recommends EU approval of Roche’s ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD)
  6:00 am GNW   F. Hoffmann-La Roche Ltd Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy
22 Apr 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd Roche purchases shares in tender offer for GenMark Diagnostics, Inc.
21 Apr 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd Roche reports solid results in the first quarter of 2021
16 Apr 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd New data for Roche’s OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis
15 Apr 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd Roche’s Evrysdi continues to improve motor function and survival in babies with Type 1 Spinal Muscular Atrophy (SMA)
13 Apr 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
12 Apr 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
08 Apr 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio
07 Apr 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd Roche launches Elecsys Anti-p53 immunoassay to aid diagnosis of various cancer types
31 Mar 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd Roche launches Elecsys Epstein-Barr Virus (EBV) immunoassay panel to improve EBV infection staging
30 Mar 2021 6:00 am GNW   F. Hoffmann-La Roche Ltd Roche’s Evrysdi approved by European Commission as first and only at home treatment for spinal muscular atrophy
26 Mar 2021 12:20 pm GNW   F. Hoffmann-La Roche Ltd Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
25 Mar 2021 4:40 pm GNW   F. Hoffmann-La Roche Ltd Roche commences tender offer for all shares of GenMark Diagnostics, Inc. for $24.05 per share in cash
23 Mar 2021 6:03 am GNW   F. Hoffmann-La Roche Ltd Roche launches new high throughput configurations for cobas pro integrated solutions to increase testing efficiency
  6:00 am GNW   F. Hoffmann-La Roche Ltd New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19
22 Mar 2021 8:00 pm GNW   F. Hoffmann-La Roche Ltd Roche provides update on tominersen programme in manifest Huntington’s disease
  6:00 am GNW   F. Hoffmann-La Roche Ltd Pivotal Phase III study shows Roche’s Tecentriq helped people with early lung cancer live longer without their disease returning
17 Mar 2021 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labs
16 Mar 2021 11:40 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche Annual General Meeting 2021
  6:03 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutations
  6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) New two-year data show Roche’s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA)
15 Mar 2021 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample
11 Mar 2021 6:03 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche’s awarded WHO prequalification for the HIV and HCV diagnostic tests on the cobas 6800/8800 Systems
  6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia
08 Mar 2021 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer
05 Mar 2021 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
26 Feb 2021 5:30 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany


Company Announcements Archive »


a d v e r t i s e m e n t